Skip to main content
. Author manuscript; available in PMC: 2018 Aug 20.
Published in final edited form as: Breast Cancer Res Treat. 2017 Feb 11;162(3):451–464. doi: 10.1007/s10549-017-4147-2

Fig. 6.

Fig. 6

Mutational status and variable responses to therapies. Cells were seeded and analyzed as described in Sect. “Materials and methods”. Results shown are representative examples of multiple independent clones and all assays were performed at least three times. Percentage of viable cells shown after 7 days in culture with a MK2206 at 1.5 uM, b BYL719 at 1.5 uM,c lapatinib at 250 nM,d everolimus (RAD001) at250 nM, e PRIMA-1 at 5 uM, and f doxorubicin at 15 nM. MCF10A = parental cells, TP53 KI = MCF10A with TP53 R248W knockin mutation, TP53 KO = MCF10A with TP53 knockout, PIK3CA KI and PIK3CA Ex.9 = MCF10A with single PIK3CA E545K knockin, PIK3CAEx.20 = MCF10A with single PIK3CA H1047R knockin, KI_9 = MCF10A with TP53 R248W knockin and PIK3CA E545K knockin,KI_20 = MCF10A with TP53 R248W knockin and PIK3CA H1047R knockin,KO_9 = MCF10A with TP53 knockout and PIK3CA E545K knockin, andKO_20 = MCF10A with TP53 knockout and PIK3CA H1047R knockin. (*p < 0.05,**p < 0.01, ***p < 0.001)